Seres Therapeutics’ highly anticipated clinical trial in ulcerative colitis failed to meet its primary endpoint, the company announced Thursday. Seres, which is focused on microbiome therapeutics, is also shutting down two ongoing open label and maintenance studies of the therapy.
Just 10% of the people who received Seres’ treatment went into remission; about the same proportion of people in the study’s placebo arm went into remission, too.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
